NCT06303713View on ClinicalTrials.gov

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

July 19, 2026

Study Completion Date

July 19, 2026

Conditions
Prostate CancerMetastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Carboplatin

Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.

DRUG

177Lu-PSMA-617

Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.

Trial Locations (3)

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER